These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 24077969)

  • 1. [National and international schizophrenia guidelines. Update 2013 regarding recommendations about antipsychotic pharmacotherapy].
    Hasan A; Wobrock T; Gaebel W; Janssen B; Zielasek J; Falkai P; ;
    Nervenarzt; 2013 Nov; 84(11):1359-60, 1362-4, 1366-8. PubMed ID: 24077969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Revised S3 guidelines on schizophrenia : Developmental process and selected recommendations].
    Hasan A; Falkai P; Lehmann I; Janssen B; Wobrock T; Zielasek J; Gaebel W
    Nervenarzt; 2020 Jan; 91(1):26-33. PubMed ID: 31605161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects.
    Hasan A; Falkai P; Wobrock T; Lieberman J; Glenthoj B; Gattaz WF; Thibaut F; Möller HJ;
    World J Biol Psychiatry; 2013 Feb; 14(1):2-44. PubMed ID: 23216388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Guideline-conform psychiatric psychotherapeutic treatment for patients with schizophrenia : A normative evaluation of necessary personnel requirements].
    Mehl S; Falkai P; Berger M; Löhr M; Rujescu D; Wolff J; Kircher T
    Nervenarzt; 2016 Mar; 87(3):286-94. PubMed ID: 26820457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophrenia.
    Falkai P; Wobrock T; Lieberman J; Glenthoj B; Gattaz WF; Möller HJ;
    World J Biol Psychiatry; 2006; 7(1):5-40. PubMed ID: 16509050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Methodology of the S3 guidelines on alcohol and tobacco-related disorders].
    Hoch E; Petersen K; Kopp I; Batra A; Mann K
    Nervenarzt; 2016 Jan; 87(1):6-12. PubMed ID: 26678625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia. Part 3: Update 2015 Management of special circumstances: Depression, Suicidality, substance use disorders and pregnancy and lactation.
    Hasan A; Falkai P; Wobrock T; Lieberman J; Glenthøj B; Gattaz WF; Thibaut F; Möller HJ;
    World J Biol Psychiatry; 2015 Apr; 16(3):142-70. PubMed ID: 25822804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Guidelines for biological treatment of substance use and related disorders, part 1: Alcoholism, first revision.
    Soyka M; Kranzler HR; Hesselbrock V; Kasper S; Mutschler J; Möller HJ;
    World J Biol Psychiatry; 2017 Mar; 18(2):86-119. PubMed ID: 28006997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance.
    Hasan A; Falkai P; Wobrock T; Lieberman J; Glenthoj B; Gattaz WF; Thibaut F; Möller HJ;
    World J Biol Psychiatry; 2012 Jul; 13(5):318-78. PubMed ID: 22834451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Diseases of the schizophrenia spectrum disorder in old age : Diagnostic and therapeutic challenges].
    Jagsch C; Hofer A
    Z Gerontol Geriatr; 2018 Nov; 51(7):744-750. PubMed ID: 30109423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia - a short version for primary care.
    Hasan A; Falkai P; Wobrock T; Lieberman J; Glenthøj B; Gattaz WF; Thibaut F; Möller HJ;
    Int J Psychiatry Clin Pract; 2017 Jun; 21(2):82-90. PubMed ID: 28498090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Guideline intentions of the German Society of Psychiatry, Psychotherapy and Nervous Diseases (DGPPN)].
    Wobrock T; Schneider F; Falkai P
    Nervenarzt; 2010 Sep; 81(9):1041-8. PubMed ID: 20798916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Guidelines for the Pharmacotherapy of Schizophrenia in Adults.
    Remington G; Addington D; Honer W; Ismail Z; Raedler T; Teehan M
    Can J Psychiatry; 2017 Sep; 62(9):604-616. PubMed ID: 28703015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Health Care Organization - The New German S3-Guideline on Alcohol-Related Disorders and its Relevance for Health Care].
    Günthner A; Weissinger V; Fleischmann H; Veltrup C; Jäpel B; Längle G; Amann K; Hoch E; Mann K
    Rehabilitation (Stuttg); 2018 Oct; 57(5):314-320. PubMed ID: 29359282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Alteration of the guidelines on pharmaceuticals of the National Committee of Physicians and Health Insurers with regard to atypical neuroleptics. Statement of the German Scoiety of Psychiatry, Psychotherapy and Neurology (DGPPN)].
    Fritze J; Schmauss M;
    Nervenarzt; 2003 Jan; 74(1):97-9. PubMed ID: 12685448
    [No Abstract]   [Full Text] [Related]  

  • 16. Antipsychotic treatment in schizophrenia: atypical options and NICE guidance.
    Mortimer AM
    Eur Psychiatry; 2003 Aug; 18(5):209-19. PubMed ID: 12927321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology.
    Barnes TR; Drake R; Paton C; Cooper SJ; Deakin B; Ferrier IN; Gregory CJ; Haddad PM; Howes OD; Jones I; Joyce EM; Lewis S; Lingford-Hughes A; MacCabe JH; Owens DC; Patel MX; Sinclair JM; Stone JM; Talbot PS; Upthegrove R; Wieck A; Yung AR
    J Psychopharmacol; 2020 Jan; 34(1):3-78. PubMed ID: 31829775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment.
    Lewis SW; Davies L; Jones PB; Barnes TR; Murray RM; Kerwin R; Taylor D; Hayhurst KP; Markwick A; Lloyd H; Dunn G
    Health Technol Assess; 2006 May; 10(17):iii-iv, ix-xi, 1-165. PubMed ID: 16707074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Minimizing the risks associated with QTc prolongation in people with schizophrenia. A consensus statement by the Cardiac Safety in Schizophrenia Group].
    Ames D; Camm J; Cook P; Falkai P; Gury C; Hurley R; Johnson G; Piepho R; Vieweg V;
    Encephale; 2002; 28(6 Pt 1):552-62. PubMed ID: 12506268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.